Advances in Clinical Trial Biostatistics (Chapman & Hall/CRC Biostatistics Series)

From aspects of early trials to complex modeling problems, this useful reference summarizes current methodology used in the design and analysis of clinical trials. Chapters are contributed by internationally revered methodologists experienced in clinical trials practice. Contributors in biostatistics, applied mathematics, and medical research summarize recent developments in the design and analysis of studies conducted in clinical research. Early chapters look at Phase I and Phase II clinical trials in drug development, and later chapters cover the design and analysis of randomized clinical trials, and examine problems in areas of compliance, the analysis of longitudinal data with missingness, and problems that have arisen in AIDS clinical trials. The audience for the book includes graduate students in biostatistics and practicing biostatisticians. A basic knowledge of clinical trials is assumed, along with a good background in classical biostatistics. Geller is director of the Office of Biostatistics Research at the National Heart, Lung, and Blood Institute, National Institutes of Health

from Aspects Of Early Trials To Complex Modeling Problems, Advances In Clinical Trial Biostatistics Summarizes Current Methodologies Used In The Design And Analysis Of Clinical Trials. Its Chapters, Contributed By Internationally Renowned Methodologists Experienced In Clinical Trials, Address Topics That Include Bayesian Methods For Phase I Clinical Trials, Adaptive Two-stage Clinical Trials, And The Design And Analysis Of Cluster Randomization Trials, Trials With Multiple Endpoints, And Therapeutic Equivalence Trials. Other Discussions Explore Bayesian Reporting, Methods Incorporating Compliance In Treatment Evaluation, And Statistical Issues Emerging From Clinical Trials In Hiv Infection.

From aspects of early trials to complex modelling problems, this reference summarizes methodology used in the design and analysis of clinical trials. Chapters have been contributed by international methodologists experienced in clinical trials practice The primary statistical objective of a cancer phase I clinical trial is to determine the optimal dose of a new treatment for subsequent clinical evaluation of efficacy.